GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance

U.S. Markets open in 3 hrs 53 mins

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
67.51+0.02 (+0.03%)
At close: 4:00PM EDT

67.62 0.11 (0.16%)
Pre-Market: 5:21AM EDT

People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close67.49
Bid67.01 x 200
Ask67.63 x 700
Day's Range67.21 - 67.87
52 Week Range65.38 - 103.10
Avg. Volume10,595,578
Market Cap88.24B
PE Ratio (TTM)6.79
Earnings DateN/A
Dividend & Yield2.08 (3.08%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters1 hour ago

    Gilead hepatitis C drug patent faces European challenge

    Two international medical humanitarian organisations said on Monday they had challenged the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment. Sofosbuvir, sold by the U.S. drugmaker as Sovaldi, is transforming the liver-destroying viral disease by offering an effective cure, but Medecins Sans Frontieres (MSF) and Medecins du Monde (MdM) said its high cost was a serious barrier. The campaigners argue that the patent on the drug is open to challenge because the science behind sofosbuvir is not new.

  • TheStreet.com5 hours ago

    Alphabet, Allergan, Ford: Doug Kass' Views

    Doug Kass shares his thoughts on Alphabet, Allergan and Ford.

  • The Best-Case Scenario for Gilead Sciences, Inc.
    Motley Fool3 days ago

    The Best-Case Scenario for Gilead Sciences, Inc.

    A look through rose-colored glasses at Gilead Sciences' possible future.